Melanoma News and Research

Latest Melanoma News and Research

Researchers design molecules that can stop colon cancer progression

A Basque research consortium has managed to halt the progress of colon cancer and its metastasis in the liver in an experimental model with mice. This advance, that may open a new path for the future treatment of such pathologies, has been achieved by creating molecules which interfere with the adhesion of tumour cells to other cells of the organism. In this way, the molecules halt both the growth of the tumour and the dissemination of the tumour to and its proliferation in other organs.

19 Feb 2013

BioAlliance Pharma to extend Validive phase II trial in head and neck cancer

BioAlliance Pharma SA, an innovative Company dedicated to the development of orphan oncology products and to supportive care products, announces the extension of its phase II clinical trial with Validive in the United States in radio/chemotherapy-induced oral mucositis prevention in patients with head and neck cancer.

15 Feb 2013

Castle Biosciences launches MyUvealMelanoma website

Castle Biosciences Inc., a leading developer of prognostic tests for rare cancers, announced today the launch of MyUvealMelanoma.com, a website created to educate newly diagnosed patients, their families and healthcare providers about the most common form of eye cancer. MyUvealMelanoma tells the story of this disease, its treatment and the importance of prognostic testing, through the experience of patients who recently faced this devastating diagnosis first-hand.

15 Feb 2013

Researchers investigate new avenue of treatment to help boost poor pancreatic cancer survival rates

Researchers at Georgia Regents University Cancer Center are investigating a new avenue of treatment to help boost poor pancreatic cancer survival rates.

13 Feb 2013

African-American and Caucasian women absorb, metabolize vitamin D at same rate

African-American women battling vitamin D deficiencies need the same dose as Caucasian women to treat the condition, according to a recent study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM).

13 Feb 2013

New cancer research to be highlighted in AACR Annual Meeting 2013

The AACR Annual Meeting 2013 will bring more than 17,000 scientists, advocates, industry leaders and other professionals to Washington, D.C., for the latest in breakthrough cancer science.

12 Feb 2013

APOBEC3B enzyme plays a key role in breast cancer

Researchers at the University of Minnesota have uncovered a human enzyme responsible for causing DNA mutations found in the majority of breast cancers. The discovery of this enzyme - called APOBEC3B - may change the way breast cancer is diagnosed and treated.

10 Feb 2013

Glimmer of hope for imatinib-resistant GIST

The monoclonal antibody SR1 can significantly inhibit gastrointestinal stromal tumor cell growth, report researchers in the Proceedings of the National Academy of Sciences.

7 Feb 2013

Hospital house calls: A way to cut costs and improve quality?

Meanwhile, a group of experts convened by the National Quality Forum has released its second annual round of recommendations on quality measures to be used in federal health programs.

6 Feb 2013

IsoRay announces presentation video on metastatic brain cancers by Cornell Weill

IsoRay Inc., a medical technology company and innovator in seed brachytherapy and medical radioisotope applications, today announced the presentation video by Cornell Weill demonstrating their techniques in the successful treatment of metastatic brain cancers using IsoRay's patented Cesium-131 (Cs-131) sutured seeds.

6 Feb 2013

Maimonides, Navidea to evaluate Lymphoseek use in lymphatic mapping for colorectal cancer

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced it has entered into an agreement to collaborate with Maimonides Medical Center to investigate the utility of Lymphoseek (technetium Tc 99m tilmanocept) Injection in lymphatic mapping procedures for colorectal cancer.

5 Feb 2013

Immune system can use melanoma's own proteins to kill off cancer cells

Though a small group of proteins, the family called Ras controls a large number of cellular functions, including cell growth, differentiation, and survival. And because the protein has a hand in cellular division, mutated Ras, which can be detected in one-third of all tumors, contributes to many human cancers by allowing for the rapid growth of diseased cells.

5 Feb 2013

Merck full-year 2012 worldwide sales decrease 2% to $47.3 billion

Merck, known as MSD outside the United States and Canada, today announced financial results for the fourth quarter and full year of 2012.

1 Feb 2013

Bioelectric signals can identify cells that are likely to develop into tumors

Biologists at Tufts University School of Arts and Sciences have discovered a bioelectric signal that can identify cells that are likely to develop into tumors. The researchers also found that they could lower the incidence of cancerous cells by manipulating the electrical charge across cells' membranes.

1 Feb 2013

Teva terminates collaboration with CureTech

Teva Pharmaceutical Industries Ltd. announced today the termination of its collaboration with CureTech Ltd.

31 Jan 2013

HIV-positive patients have higher incidence of non-melanoma skin cancers

HIV-positive patients have a higher incidence of non-melanoma skin cancers, according to a Kaiser Permanente study that appears in the current online issue of the Journal of the National Cancer Institute. Specifically, basal cell and squamous cell carcinomas occur more than twice as often among HIV-positive individuals compared to those who are HIV-negative.

30 Jan 2013

Red coloration might represent some physiological benefit: Research

Red coloration-historically seen as costly in vertebrates-might represent some physiological benefit after all, according to research published in the journal Physiological and Biochemical Zoology.

29 Jan 2013

Cancer risk independent of folic acid supplementation

Folic acid supplementation does not increase or decrease the risk for cancer, suggests research published in The Lancet.

28 Jan 2013

Telomerase gene mutation immortalizes deadly skin cancer

About ten percent of all cases of malignant melanoma are familial cases. The genome of affected families tells scientists a lot about how the disease develops. Prof. Dr. Rajiv Kumar of the German Cancer Research Center together with Prof. Dr. Dirk Schadendorf from Essen University Hospital studied a family where 14 family members were affected by malignant melanoma.

28 Jan 2013

Researchers identify cancer-associated mutations

Two new mutations that collectively occur in 71 percent of malignant melanoma tumors have been discovered in what scientists call the "dark matter" of the cancer genome, where cancer-related mutations haven't been previously found.

25 Jan 2013